Department of Pathology, The Peking University, First Hospital, Beijing 100034, China.
Hum Pathol. 2012 Aug;43(8):1197-205. doi: 10.1016/j.humpath.2011.08.021. Epub 2011 Dec 30.
The aim of this study was to determine the clinicopathological impact of PIK3CA mutations and phosphatidylinositol 3'-kinase pathway alterations in endometrial cancers in Chinese women. The PIK3CA mutation status was analyzed by sequencing in 94 tumors. The status of phosphatase and tensin homolog, p-(Ser/Thr)AKT, human epidermal growth factor receptor 2, p53, and estrogen and progesterone receptor was assessed in 102 tumors using immunohistochemistry. Biomarker status was correlated with clinicopathologic variables and with patient survival. We found that 28 mutations occurred in the helical domain encoded by exon 9 of PIK3CA and 16 occurred in the kinase domain (exon 20). Mutations of both exons were more common in low-grade than in high-grade endometrioid carcinomas, and the correlation between exon 9 mutation and lower grade was statistically significant (P = .045). In univariate analysis, phosphatidylinositol 3'-kinase pathway activation (defined as PIK3CA mutation and/or phosphatase and tensin homolog loss) was associated with a favorable prognosis (P = .034) and showed an increased predictive power when combined with expression of p-AKT, the phosphatidylinositol 3'-kinase pathway downstream effector (P = .022). In multivariate analysis, phosphatidylinositol 3'-kinase pathway activation was not an independent predictor of disease-free survival (P = .091). Interestingly, in the estrogen receptor-negative subgroup, the phosphatidylinositol 3'-kinase pathway alteration was significantly related to prolonged patient survival (P = .048), whereas this association was not present in the estrogen receptor-positive subgroup (P > .05). Our findings suggest that phosphatidylinositol 3'-kinase pathway alteration might have a favorable prognostic impact on endometrial cancers in Chinese women. Furthermore, the function of the phosphatidylinositol 3'-kinase pathway might be affected by estrogen receptor status.
本研究旨在确定 PIK3CA 突变和磷脂酰肌醇 3'-激酶途径改变在中国女性子宫内膜癌中的临床病理影响。通过测序分析了 94 例肿瘤的 PIK3CA 突变状态。采用免疫组织化学法检测了 102 例肿瘤中磷酸酶和张力蛋白同源物、p-(Ser/Thr)AKT、人表皮生长因子受体 2、p53 和雌激素及孕激素受体的状态。评估了生物标志物状态与临床病理变量和患者生存的相关性。我们发现,PIK3CA 外显子 9 编码的螺旋结构域发生了 28 个突变,外显子 20 编码的激酶结构域发生了 16 个突变。外显子 9 和外显子 20 的突变在低级别子宫内膜样癌中比在高级别子宫内膜样癌中更为常见,外显子 9 突变与低级别之间存在统计学显著相关性(P =.045)。在单因素分析中,磷脂酰肌醇 3'-激酶途径激活(定义为 PIK3CA 突变和/或磷酸酶和张力蛋白同源物缺失)与较好的预后相关(P =.034),并且当与磷酸化 AKT 的表达相结合时,预测能力增加,磷酸化 AKT 是磷脂酰肌醇 3'-激酶途径的下游效应物(P =.022)。在多因素分析中,磷脂酰肌醇 3'-激酶途径激活不是无病生存的独立预测因子(P =.091)。有趣的是,在雌激素受体阴性亚组中,磷脂酰肌醇 3'-激酶途径改变与患者生存延长显著相关(P =.048),而在雌激素受体阳性亚组中则不存在这种相关性(P >.05)。我们的研究结果表明,磷脂酰肌醇 3'-激酶途径改变可能对中国女性的子宫内膜癌有良好的预后影响。此外,磷脂酰肌醇 3'-激酶途径的功能可能受雌激素受体状态的影响。